Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Mar;86(6):2040–2044. doi: 10.1073/pnas.86.6.2040

Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model.

E Zocchi 1, M Tonetti 1, C Polvani 1, L Guida 1, U Benatti 1, A De Flora 1
PMCID: PMC286842  PMID: 2928317

Abstract

Doxorubicin-loaded, glutaraldehyde-treated murine erythrocytes, once reinjected into circulation, are rapidly taken up by liver and lungs and behave as an organ-targeted, slow delivery system for the encapsulated drug. The antitumor activity of encapsulated doxorubicin (former generic name, adriamycin) was compared with that of the free drug in a murine hepatic and pulmonary tumor model. This was obtained by intrasplenic injection of L1210 lymphoma cells followed by splenectomy. Different schedules of treatment of tumor-bearing mice with erythrocyte-encapsulated or free doxorubicin were investigated. The optimal schedule of treatment for free doxorubicin proved to be i.v. bolus administration on the day of splenectomy. Under these conditions, the dose producing 50% inhibition of metastatic growth in the liver, as measured by inhibition of 5-[125I]iodo-2'-deoxyuridine uptake 9 days after tumor induction, was 6.3 mg/kg for free doxorubicin and 0.48 mg/kg for the encapsulated drug. In these conditions pulmonary tumor development was even more efficiently prevented by encapsulated doxorubicin as compared with the free drug. The values of the therapeutic index (TI), defined as the ratio between the maximal tolerated dose (LD10) and the minimal effective dose (ED90, producing 90% inhibition of liver metastatic growth), were 4.2 and 1.8 for encapsulated and free doxorubicin, respectively.

Full text

PDF
2040

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonmassar E., Houchens D. P., Fioretti M. C., Goldin A. Uptake of 5-iododeoxyuridine as a measure of tumor growth and tumor inhibition. Chemotherapy. 1975;21(6):321–329. doi: 10.1159/000221877. [DOI] [PubMed] [Google Scholar]
  2. De Flora A., Benatti U., Guida L., Zocchi E. Encapsulation of adriamycin in human erythrocytes. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7029–7033. doi: 10.1073/pnas.83.18.7029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. DeLoach J. R., Corrier D. E. Subcutaneous administration of carrier erythrocytes: slow release of entrapped agent. Biotechnol Appl Biochem. 1988 Aug;10(4):359–364. [PubMed] [Google Scholar]
  4. Deloach J., Peters S., Pinkard O., Glew R., Ihler G. Effect of glutaraldehyde treatment on enzyme-loaded erythrocytes. Biochim Biophys Acta. 1977 Feb 28;496(2):507–515. doi: 10.1016/0304-4165(77)90332-4. [DOI] [PubMed] [Google Scholar]
  5. Di Marco A., Gaetani M., Scarpinato B. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969 Feb;53(1):33–37. [PubMed] [Google Scholar]
  6. Di Marco A., Lenaz L., Casazza A. M., Scarpinato B. M. Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep. 1972 Apr;56(2):153–161. [PubMed] [Google Scholar]
  7. Lafreniere R., Rosenberg S. A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst. 1986 Feb;76(2):309–322. [PubMed] [Google Scholar]
  8. SKIPPER H. E., SCHMIDT L. H. A manual on quantitative drug evaluation in experimental tumor systems. I. Background, description of criteria, and presentation of quantitative therapeutic data on various classes of drugs obtained in diverse experimental tumor systems. Cancer Chemother Rep. 1962 Apr;17:1–143. [PubMed] [Google Scholar]
  9. Shapiro J., Jersky J., Katzav S., Feldman M., Segal S. Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. J Clin Invest. 1981 Sep;68(3):678–685. doi: 10.1172/JCI110303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sullivan S. M., Huang L. Enhanced delivery to target cells by heat-sensitive immunoliposomes. Proc Natl Acad Sci U S A. 1986 Aug;83(16):6117–6121. doi: 10.1073/pnas.83.16.6117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966 Apr;36(4):641–645. doi: 10.1093/jnci/36.4.641. [DOI] [PubMed] [Google Scholar]
  12. Yang H. M., Reisfeld R. A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1189–1193. doi: 10.1073/pnas.85.4.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Zocchi E., Guida L., Benatti U., Canepa M., Borgiani L., Zanin T., De Flora A. Hepatic or splenic targeting of carrier erythrocytes: a murine model. Biotechnol Appl Biochem. 1987 Oct;9(5):423–434. [PubMed] [Google Scholar]
  14. Zocchi E., Tonetti M., Polvani C., Guida L., Benatti U., De Flora A. In vivo liver and lung targeting of adriamycin encapsulated in glutaraldehyde-treated murine erythrocytes. Biotechnol Appl Biochem. 1988 Dec;10(6):555–562. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES